Cardiol Therapeutics Class Stock Technical Analysis
| CRDL Stock | USD 1.58 0.05 3.27% |
As of the 29th of November, Cardiol Therapeutics shows the Standard Deviation of 3.75, risk adjusted performance of (0.04), and Mean Deviation of 2.91. Cardiol Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiol Therapeutics information ratio and potential upside to decide if Cardiol Therapeutics is priced correctly, providing market reflects its regular price of 1.58 per share. Please also double-check Cardiol Therapeutics Class jensen alpha, which is currently at (0.32) to validate the company can sustain itself at a future point.
Cardiol Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Cardiol, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to CardiolCardiol |
Cardiol Therapeutics Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 4.49 | Strong Buy | 5 | Odds |
Most Cardiol analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cardiol stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cardiol Therapeutics, talking to its executives and customers, or listening to Cardiol conference calls.
Cardiol Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Cardiol Therapeutics Technical Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Cardiol Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Cardiol Therapeutics Trend Analysis
Use this graph to draw trend lines for Cardiol Therapeutics Class. You can use it to identify possible trend reversals for Cardiol Therapeutics as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Cardiol Therapeutics price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Cardiol Therapeutics Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Cardiol Therapeutics Class applied against its price change over selected period. The best fit line has a slop of 0.0091 , which may suggest that Cardiol Therapeutics Class market price will keep on failing further. It has 122 observation points and a regression sum of squares at 3.12, which is the sum of squared deviations for the predicted Cardiol Therapeutics price change compared to its average price change.About Cardiol Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Cardiol Therapeutics Class on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Cardiol Therapeutics Class based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Cardiol Therapeutics price pattern first instead of the macroeconomic environment surrounding Cardiol Therapeutics. By analyzing Cardiol Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Cardiol Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Cardiol Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 (projected) | Days Sales Outstanding | 1.7K | 1.5K | PTB Ratio | 2.51 | 2.38 |
Cardiol Therapeutics November 29, 2024 Technical Indicators
Most technical analysis of Cardiol help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Cardiol from various momentum indicators to cycle indicators. When you analyze Cardiol charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.36) | |||
| Mean Deviation | 2.91 | |||
| Coefficient Of Variation | (1,601) | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.04 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.37) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.73) | |||
| Potential Upside | 5.62 | |||
| Skewness | 0.4604 | |||
| Kurtosis | 0.8024 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.